Statins, commonly coprescribed drugs, and concomitant risk factors: A protective, neutral, or harmful association with common cancer types development: A 10-year multicentric retrospective lebanese study
Medicine (Baltimore). 2023 Sep 29;102(39):e34562. doi: 10.1097/MD.0000000000034562.ABSTRACTElevated blood levels of low-density lipoprotein cholesterol are a major cardiovascular risk factor, and cholesterol-lowering drugs are among the most prescribed drugs worldwide. Cancer is the second leading cause of death after cardiovascular diseases. The relationship between cancer development and statins intake is controversial, and there are no clear studies in Lebanon and the Middle East concerning this topic. Hence, our study aimed to search for any possible association of statin intake as well as other medications (proton pum...
Source: Cancer Control - September 29, 2023 Category: Cancer & Oncology Authors: Issam G Chalhoub Rita T Boulos Yara G Dagher Sandra El Helou Karen G Haifa Bachir Atallah Fadi Nasr Issam Kassab Mirna N Chahine Source Type: research
Prevalence and associated factors of hyperuricemia among Chinese patients with diabetes: a cross-sectional study
CONCLUSION: Hyperuricemia is highly prevalent in patients with diabetes, especially in males. In addition to traditionally associated factors, fenofibrate and SGLT-2 inhibitors were also associated with the risk of hyperuricemia.REGISTRATION: The study protocol was registered in the Chinese Clinical Trial Registry (http://www.chictr.org.cn/), and the registration number was ChiCTR 2100042742.PMID:37719790 | PMC:PMC10501065 | DOI:10.1177/20420188231198620 (Source: Adv Data)
Source: Adv Data - September 18, 2023 Category: Epidemiology Authors: Shiyi Sun Lihong Chen Dawei Chen Yan Li Guanjian Liu Lin Ma Jun Li Fangwei Cao Xingwu Ran Source Type: research
Fixed Combination for the Treatment of Dyslipidaemia
AbstractPurpose of ReviewIt is clear from epidemiological studies that patients at high and very-high risk of atherosclerotic cardiovascular diseases (ASCVD) risk do not reach lipid guideline –recommended targets. Thus, fixed-dose combinations of statins/ezetimibe, bempedoic acid/ezetimibe and statins/fibrates may represent a further armamentarium in the field of lipid-lowering approaches in these individuals.Recent FindingsThe combination therapy of moderate-intensity statin with ezetimibe is not inferior to high-intensity statin monotherapy in reducing cardiovascular outcomes. Drug discontinuation or dose reduction is ...
Source: Current Atherosclerosis Reports - September 16, 2023 Category: Cardiology Source Type: research
Racial/ethnic and socioeconomic disparities in achievement of treatment goals within a clinical trial: a secondary analysis of the ACCORD trial
Conclusions/interpretationRacially/ethnically minoritised participants in the ACCORD trial were less likely to achieve high-burden (glycaemic) treatment goals but were generally similarly likely to achieve goals of less intensive interventions. Differences in glycaemic treatment goal achievement were partially mediated by differences in medication use but not mediated by hypoglycaemia, change in BMI or study visit attendance.Graphical Abstract (Source: Diabetologia)
Source: Diabetologia - September 16, 2023 Category: Endocrinology Source Type: research
Effect of fenofibrate and selective PPAR α modulator (SPPARMα), pemafibrate on KATP channel activity and insulin secretion
BMC Res Notes. 2023 Sep 11;16(1):202. doi: 10.1186/s13104-023-06489-7.ABSTRACTOBJECTIVE: Insulin secretion is regulated by ATP-sensitive potassium (KATP) channels in pancreatic beta-cells. Peroxisome proliferator-activated receptors (PPAR) α ligands are clinically used to treat dyslipidemia. A PPARα ligand, fenofibrate, and PPARγ ligands troglitazone and 15-deoxy-∆12,14-prostaglandin J2 are known to close KATP channels and induce insulin secretion. The recently developed PPARα ligand, pemafibrate, became a new entry for treating dyslipidemia. Because pemafibrate is reported to improve glucose intolerance in mice trea...
Source: Cell Research - September 12, 2023 Category: Cytology Authors: Shigeki Kitamura Naoya Murao Shoko Yokota Masaru Shimizu Tomoyuki Ono Yusuke Seino Atsushi Suzuki Yuko Maejima Kenju Shimomura Source Type: research
Effect of fenofibrate and selective PPAR α modulator (SPPARMα), pemafibrate on KATP channel activity and insulin secretion
Insulin secretion is regulated by ATP-sensitive potassium (KATP) channels in pancreatic beta-cells. Peroxisome proliferator-activated receptors (PPAR) α ligands are clinically used to treat dyslipidemia. A PPARα ... (Source: BMC Research Notes)
Source: BMC Research Notes - September 11, 2023 Category: Research Authors: Shigeki Kitamura, Naoya Murao, Shoko Yokota, Masaru Shimizu, Tomoyuki Ono, Yusuke Seino, Atsushi Suzuki, Yuko Maejima and Kenju Shimomura Tags: Research Note Source Type: research
Pregnancy-related Adverse Events associated with statins: A Real-World Pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS)
CONCLUSIONS: Statins did not increase the risk of pregnancy-related AEs, including abortion, abortion spontaneous or stillbirth/fetal death. However, we did find significant disproportionality signals for preterm birth and low birth weight associated with pravastatin, and lovastatin was related to a higher proportion of fetal complications. The results in this study may provide evidence on the safety of statins during pregnancy, which need to be verified in further investigations.PMID:37612600 | DOI:10.1080/14740338.2023.2251888 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - August 23, 2023 Category: Drugs & Pharmacology Authors: Tingxi Wu Yanfeng Shi Bin Zhu Dandan Li Zhe Li Zhigang Zhao Yang Zhang Source Type: research
Differential effects on renal function and glucose metabolism of renal dependent bezafibrate and non-renal dependent pemafibrate in patients with hypertriglyceridemia
CONCLUSION: Our findings indicate that switching from bezafibrate to pemafibrate produces a significant decrease in serum creatinine and increases in eGFR and hemoglobin A1c in patients with hypertriglyceridemia, suggesting that the effects on renal function and glucose metabolism differ among fibrates.PMID:37548458 | DOI:10.5414/CP204408 (Source: Clinical Pharmacology and Therapeutics)
Source: Clinical Pharmacology and Therapeutics - August 7, 2023 Category: Drugs & Pharmacology Authors: Mana Nishida Takeshi Horio Yusuke Fukuda Yuki Hayakawa Yu Tateishi Mayumi Akai Masanori Emoto Takamasa Hasegawa Masahito Imanishi Source Type: research
Differential effects on renal function and glucose metabolism of renal dependent bezafibrate and non-renal dependent pemafibrate in patients with hypertriglyceridemia
CONCLUSION: Our findings indicate that switching from bezafibrate to pemafibrate produces a significant decrease in serum creatinine and increases in eGFR and hemoglobin A1c in patients with hypertriglyceridemia, suggesting that the effects on renal function and glucose metabolism differ among fibrates.PMID:37548458 | DOI:10.5414/CP204408 (Source: International Journal of Clinical Pharmacology and Therapeutics)
Source: International Journal of Clinical Pharmacology and Therapeutics - August 7, 2023 Category: Drugs & Pharmacology Authors: Mana Nishida Takeshi Horio Yusuke Fukuda Yuki Hayakawa Yu Tateishi Mayumi Akai Masanori Emoto Takamasa Hasegawa Masahito Imanishi Source Type: research
Quiz case: a clinical reasoning challenge in the emergency stroke setting
AbstractA right-handed woman in her 80s was admitted to the emergency department 1 h after sudden-onset global aphasia and right-sided hemiparesis. Medical history included arterial hypertension, dyslipidemia, hyperuricemia, aortic stenosis, osteoporosis, and recent pulmonary embolism. Medication consisted of apixaban, bisoprolol, hydrochlorothiazide, allopurinol, fenofibrate, and vitamin D. Vital parameters (blood pressure, heart rate, body temperature, oxygen saturation) and glycemia were all within normal range. Electrocardiogram showed a first-degree atrioventricular block. The patient was promptly transported to the e...
Source: Neurological Sciences - August 5, 2023 Category: Neurology Source Type: research
PPAR- Α agonist fenofibrate and 11,12-epoxyeicosatrienoic acid suppresses endoplasmic reticulum stress-induced apoptosis and enhances cell viability in diabetic rat hearts
Background and Aims: Diabetes mellitus (DM) is associated with an increased risk of cardiovascular diseases, which is related with prolonged endoplasmic reticulum (ER) stress and the activation of apoptotic pathways. Cytochrome P450 (CYP) and its arachidonic acid metabolites 11,12-epoxyeicosatrienoic acid (11,12-EET) have protective roles in heart failure by protecting endothelial cells and myocytes from apoptosis. However, the link between cardioprotective roles of CYP epoxygenase and ER stress has not been well known in diabetic cardiomyopathy. (Source: Atherosclerosis)
Source: Atherosclerosis - August 1, 2023 Category: Cardiology Authors: S. Kim, X. Gao, W.S. Yun, L. Jung, Y. Kim, S. Lee, S. Lee, K.-S. Rhee, J. Chae Source Type: research
